Table 5.
Prostate cancer risk by haplotypes of CYP19A1 in the PCPT
| Haplotype | Placebo arm | Finasteride arm | ||
|---|---|---|---|---|
| Estimated % | ORa (95% CI) | Estimated % | ORa (95% CI) | |
| CYP19A1 (rs700518, rs2445765, rs700519) | ||||
| GCC | 10.1 | 1.00 | 10.5 | 1.00 |
| ACC | 6.3 | 1.52 (0.94–2.45) | 8.1 | 1.37 (0.82–2.28) |
| AGC | 38.8 | 1.29 (0.99–1.68) | 36.6 | 1.49 (1.10–2.04) |
| GGC | 41.7 | 1.42 (1.06–1.90) | 41.5 | 1.70 (1.20–2.41) |
| Other# | 3.1 | 1.91 (1.19–3.07) | 3.3 | 1.43 (0.83–2.47) |
Bold values indicate significant/borderline significant findings.
a
Adjusted for age and family history.
b
All haplotypes with frequency less than 5% combined.